FREDUN PHARMACEUTICALS L Latest Share Price (FREDUN)
TODAY IN ONE LINE
FREDUN fell 1.6%, lagging Nifty's 2.0% move.
With a market cap of ₹2,446.64 Cr., it trades at a P/E of 45.87. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
FREDUN PHARMACEUTICALS L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Promoter BuyingPromoters increased holdings by 0.40% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest FREDUN PHARMACEUTICALS L News
What changed recently?
Recent events, corporate actions, and announcements.
FREDUN PHARMACEUTICALS L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for FREDUN PHARMACEUTICALS L, framed against the sector median so the premium or discount is obvious at a glance.
FREDUN PHARMACEUTICALS L trades at a P/E of 45.87× and P/B of 7.35×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
FREDUN PHARMACEUTICALS L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for FREDUN PHARMACEUTICALS L — derived from the latest tape, not yesterday's close.
FREDUN PHARMACEUTICALS L last traded at ₹1,472.6 with an intraday range of ₹1,422.4–₹1,506.9 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1472.60| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1681.20 | +208.60 | +14.17% |
| R3 | 1596.70 | +124.10 | +8.43% |
| R2 | 1551.80 | +79.20 | +5.38% |
| R1 | 1512.20 | +39.60 | +2.69% |
| PIVOT | 1467.30 | -5.30 | -0.36% |
| CURRENT | 1472.60 | — | — |
| S1 | 1427.70 | -44.90 | -3.05% |
| S2 | 1382.80 | -89.80 | -6.10% |
| S3 | 1343.20 | -129.40 | -8.79% |
| S4 | 1258.70 | -213.90 | -14.53% |
FREDUN is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹1459–₹1506.9
Trading Inside opening range
FREDUN PHARMACEUTICALS L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for FREDUN PHARMACEUTICALS L — consolidated or standalone — with margins, YoY growth and key ratios inline.
FREDUN PHARMACEUTICALS L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,446.64 Cr. and reported EPS of ₹7.94.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 633 | 633 ▲ 0.0% |
| Sales Growth YoY %Derived | 40.21% | 40.21% |
| Other Income | 6 | 6 ▲ 0.0% |
| Total Income | 639 | 639 ▲ 0.0% |
| 449 | 449 ▲ 0.0% | |
| Gross ProfitDerived | 184 | 184 ▲ 0.0% |
| Gross Margin %Derived | 29.09% | 29.09% |
| 96 | 96 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 89 | 89 ▲ 0.0% |
| OPM %Derived | 14.01% | 14.01% |
| 48 | 48 ▲ 0.0% | |
| Profit Before Tax (PBT) | 47 | 47 ▲ 0.0% |
| 14 | 14 ▲ 0.0% | |
| Effective Tax %Derived | 30.59% | 30.59% |
| Total Profit for Period | 33 | 33 ▲ 0.0% |
| Less: Non-controlling Interests | — | — |
| Net Profit (Owner's PAT)Derived | 33 | 33 ▲ 0.0% |
| Net Profit Margin %Derived | 5.15% | 5.15% |
| PAT Growth YoY %Derived | 65.28% | 65.28% |
| Earnings Per Share (EPS ₹) | 19.87 | 19.87 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 592 | 592 ▲ 0.0% |
| Material Cost % of RevenueDerived | 75.91% | 75.91% |
| Employee Cost % of RevenueDerived | 5.20% | 5.20% |
| Other Cost % of RevenueDerived | 9.88% | 9.88% |
| Interest Coverage (x)Derived | 2.05x | 2.05x |
| Period | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|
| Revenue from Operations | 452 | 452 ▲ 0.0% | 633 ▲ 40.2% | 633 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | 40.21% | 40.21% | |
| Other Income | 5 | 5 ▲ 0.0% | 6 ▲ 27.1% | 6 ▲ 0.0% | |
| Total Income | 456 | 456 ▲ 0.0% | 639 ▲ 40.1% | 639 ▲ 0.0% | |
330 | 330 ▲ 0.0% | 449 ▲ 36.1% | 449 ▲ 0.0% | ||
| Gross ProfitDerived | 122 | 122 ▲ 0.0% | 184 ▲ 51.4% | 184 ▲ 0.0% | |
| Gross Margin %Derived | 26.94% | 26.94% | 29.09% | 29.09% | |
71 | 71 ▲ 0.0% | 96 ▲ 33.9% | 96 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 50 | 50 ▲ 0.0% | 89 ▲ 76.3% | 89 ▲ 0.0% | |
| OPM %Derived | 11.15% | 11.15% | 14.01% | 14.01% | |
27 | 27 ▲ 0.0% | 48 ▲ 73.4% | 48 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 27 | 27 ▲ 0.0% | 47 ▲ 70.9% | 47 ▲ 0.0% | |
8 | 8 ▲ 0.0% | 14 ▲ 85.4% | 14 ▲ 0.0% | ||
| Effective Tax %Derived | 28.20% | 28.20% | 30.59% | 30.59% | |
| Total Profit for Period | 20 | 20 ▲ 0.0% | 33 ▲ 65.3% | 33 ▲ 0.0% | |
| Less: Non-controlling Interests | 0 | 0 ▲ 0.0% | — ▼ 100.0% | — | |
| Net Profit (Owner's PAT)Derived | 20 | 20 ▲ 0.0% | 33 ▲ 65.3% | 33 ▲ 0.0% | |
| Net Profit Margin %Derived | 4.37% | 4.37% | 5.15% | 5.15% | |
| PAT Growth YoY %Derived | — | — | 65.28% | 65.28% | |
| Earnings Per Share (EPS ₹) | 13.93 | 13.93 ▲ 0.0% | 19.87 ▲ 42.6% | 19.87 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 2 ▲ 15.9% | 2 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 0.0% | 0 ▲ 149.3% | 0 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 429 | 429 ▲ 0.0% | 592 ▲ 38.1% | 592 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 71.72% | 71.72% | 75.91% | 75.91% | |
| Employee Cost % of RevenueDerived | 4.92% | 4.92% | 5.20% | 5.20% | |
| Other Cost % of RevenueDerived | 10.87% | 10.87% | 9.88% | 9.88% | |
| Interest Coverage (x)Derived | 2.02x | 2.02x | 2.05x | 2.05x |
FREDUN PHARMACEUTICALS L segment analysis : revenue and profit mix.
Disclosed business segments at FREDUN PHARMACEUTICALS L with their share of revenue and profit, switchable between consolidated and standalone reporting.
FREDUN PHARMACEUTICALS L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for FREDUN PHARMACEUTICALS L.
Our AI distills the core fundamental drivers supporting FREDUN PHARMACEUTICALS L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 60 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Income thesis breaks if the dividend is cut or yield falls below 0.03%.
FREDUN PHARMACEUTICALS L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — FREDUN PHARMACEUTICALS L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
FREDUN PHARMACEUTICALS L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for FREDUN PHARMACEUTICALS L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
FREDUN PHARMACEUTICALS L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for FREDUN PHARMACEUTICALS L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in FREDUN PHARMACEUTICALS L stood at 39.1% of traded volume, against a 20-day average of 44.9%.
FREDUN PHARMACEUTICALS L announcements: results, concalls, ratings, M&A.
Filings FREDUN PHARMACEUTICALS L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
FREDUN PHARMACEUTICALS L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 84 documents below.
Insider Trading / SAST
Intimation of Trading Window Closure
Company Update
Revised Allotment of Equity Shares pursuant to conversion of warrants.
Company Update
Revised Outcome of Board Meeting Dated 16th September, 2026
Company Update
Allotment of 271200 Equity Shares upon Conversion of Warrants.
Investor decks & rating reports.
FREDUN PHARMACEUTICALS L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue FREDUN PHARMACEUTICALS L has declared, sequenced by announce and record date.
FREDUN PHARMACEUTICALS L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About FREDUN PHARMACEUTICALS L: business, sector, key facts.
What FREDUN PHARMACEUTICALS L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
FREDUN PHARMACEUTICALS L is a listed Indian equity.
FREDUN PHARMACEUTICALS L
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA HEALTHCARE (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about FREDUN PHARMACEUTICALS L (FREDUN).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of FREDUN PHARMACEUTICALS L (FREDUN)?
The current share price of FREDUN PHARMACEUTICALS L (FREDUN) is ₹1,472.60. Today, the stock has declined by ₹24.40 (1.63%), trading in a range of ₹1,422.40 to ₹1,506.90. The stock opened at ₹1,504.50 with a trading volume of 1,32,065 shares.
02Is FREDUN PHARMACEUTICALS L stock a good investment for long-term?
FREDUN PHARMACEUTICALS L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,446.64 Cr., P/E ratio of 45.87, ROE of 0%, and ROCE of 0%. The dividend yield stands at 0.05%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of FREDUN PHARMACEUTICALS L stock?
The 52-week high price of FREDUN PHARMACEUTICALS L (FREDUN) is ₹1,665.00, while the 52-week low is ₹1,195.20. Currently trading at ₹1,472.60, the stock is 23.21% above its 52-week low and 11.56% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy FREDUN PHARMACEUTICALS L stock at the current price?
Whether to buy FREDUN PHARMACEUTICALS L stock at ₹1,472.60 depends on multiple factors. The stock is currently trading with a P/E ratio of 45.87 and P/B ratio of 7.35. Today's performance shows a loss of 1.63%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of FREDUN PHARMACEUTICALS L and when is the next dividend?
FREDUN PHARMACEUTICALS L offers a dividend yield of 0.05%, which means for every ₹100 invested at the current price of ₹1,472.60, you can expect to receive approximately ₹0.05 annually as dividends. The face value of the stock is ₹3.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06How is FREDUN PHARMACEUTICALS L stock performing today in the market?
FREDUN PHARMACEUTICALS L stock opened at ₹1,504.50 and is currently trading at ₹1,472.60, showing a decline of ₹24.40 (1.63%). The intraday high is ₹1,506.90 and low is ₹1,422.40. The trading volume stands at 1,32,065 shares, indicating moderate market participation today.
07What is the P/E ratio of FREDUN PHARMACEUTICALS L and what does it indicate?
FREDUN PHARMACEUTICALS L has a Price-to-Earnings (P/E) ratio of 45.87, which means investors are willing to pay 45.87 for every ₹1 of earnings. With an EPS of ₹7.94, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
08What is the market capitalization of FREDUN PHARMACEUTICALS L?
FREDUN PHARMACEUTICALS L has a market capitalization of ₹2,446.64 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,472.60) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
The data, ratios and commentary about FREDUN PHARMACEUTICALS L (FREDUN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.